$21.16
1.20% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US3596641098
Symbol
FLGT

Fulgent Genetics Stock price

$21.16
-1.71 7.48% 1M
-0.53 2.44% 6M
-7.75 26.81% YTD
-6.03 22.18% 1Y
-66.41 75.84% 3Y
+10.93 106.84% 5Y
+11.98 130.50% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.25 1.20%
ISIN
US3596641098
Symbol
FLGT
Sector

Key metrics

Market capitalization $633.50m
Enterprise Value $331.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 28.33
EV/Sales (TTM) EV/Sales 1.14
P/S ratio (TTM) P/S ratio 2.18
P/B ratio (TTM) P/B ratio 0.56
Revenue growth (TTM) Revenue growth -5.42%
Revenue (TTM) Revenue $290.71m
EBIT (operating result TTM) EBIT $-71.38m
Free Cash Flow (TTM) Free Cash Flow $11.70m
Cash position $311.71m
EPS (TTM) EPS $-5.48
P/E forward negative
P/S forward 2.25
EV/Sales forward 1.18
Short interest 4.35%
Show more

Is Fulgent Genetics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Fulgent Genetics Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Fulgent Genetics forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Fulgent Genetics forecast:

Buy
33%
Hold
67%

Financial data from Fulgent Genetics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
291 291
5% 5%
100%
- Direct Costs 185 185
15% 15%
64%
106 106
17% 17%
36%
- Selling and Administrative Expenses 106 106
12% 12%
36%
- Research and Development Expense 47 47
32% 32%
16%
-47 -47
20% 20%
-16%
- Depreciation and Amortization 24 24
41% 41%
8%
EBIT (Operating Income) EBIT -71 -71
12% 12%
-25%
Net Profit -163 -163
236% 236%
-56%

In millions USD.

Don't miss a Thing! We will send you all news about Fulgent Genetics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulgent Genetics Stock News

Positive
Seeking Alpha
2 days ago
Fulgent Genetics is transitioning from a diagnostic business to a fully integrated healthcare company, with a focus on oncology. Despite past reliance on COVID-19 test revenues, Fulgent's core business has grown significantly, with a strong balance sheet and zero debt. Trading below a conservative estimate of liquidation value, Fulgent presents a rare investment opportunity with potential for f...
Positive
Seeking Alpha
18 days ago
Fulgent Genetics' core revenue grew just 3% in H1 2024, with full-year guidance of $280 million implying a step-up to 11% growth in H2 and 7% for FY 2024. Growth in precision diagnostics (+35% in H1 2024) and gross margin expansion (+650 basis points) were the two bright spots in first half results. Headwinds in anatomic pathology and BioPharma services will soften starting H2 2024, paving the ...
Positive
The Motley Fool
about 2 months ago
The company's revenue was $71.0 million, up from $67.9 million in Q2 2023. Its non-GAAP income improved to $4.7 million, while its GAAP loss stood at $8.7 million.
More Fulgent Genetics News

Company Profile

Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Head office United States
CEO Ming Hsieh
Employees 1,184
Founded 2016
Website www.fulgentgenetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today